The Quantellect read.As of Nov 19, 2026, 6 active firms cover Castle Biosciences Inc: 6 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $40.00 to $52.00, so the covering firms are broadly aligned. The average target of $44.33 sits 33% above the current $33.39. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.30 next quarter toward $-0.63 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Buy
Strong Buy00%
Buy6100%
Neutral00%
Sell00%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$44.33
+32.8% upside
Average target across 6 active firms as of Nov 19, 2026 vs $33.39 current
Highest Target$52.00
Average Target$44.33
Lowest Target$40.00
Detailed analyst forecasts for CSTL
Showing 1–6 of 6 named analysts shown · 6 active firms in the rating projection
As of Nov 19, 2026, 6 of 6 active firms rate CSTL a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CSTL EPS & revenue forecast
EPS · NEXT QUARTER
$-0.30
Range $-0.46 – $-0.16 · 8 analysts · -39% YoY
Next period, 8 analysts expect Castle Biosciences Inc to earn $-0.30 a share (range $-0.46 – $-0.16), versus $-0.49 a year earlier. Full-year consensus is $-0.82, growing to $-0.63 the year after.
REVENUE · NEXT QUARTER
$101.0M
Range $92.2M – $107.2M · 8 analysts · +21% YoY
Revenue is expected to reach $101.0M (range $92.2M – $107.2M), +20.7% year-over-year. Full-year consensus is $392.3M, rising to $434.0M next year.
Top analysts covering Castle Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CSTL.
#1
Puneet Souda
Leerink Partners · Rank #30
Buy
$35.00+4.8% to target
Overall win rate
57%
+ Follow
#2
MC
Mason Carrico
Stephens & Co. · Rank #178
Buy
$41.00+22.8% to target
Overall win rate
40%
+ Follow
#3
SJ
Sung Ji Nam
Scotiabank · Rank #186
Buy
$40.00+19.8% to target
Overall win rate
47%
+ Follow
#4
KM
Kyle Mikson
Canaccord Genuity · Rank #202
Buy
$40.00+19.8% to target
Overall win rate
40%
+ Follow
#5
Mark Massaro
BTIG · Rank #220
Buy
$44.00+31.8% to target
Overall win rate
44%
+ Follow
CSTL stock forecast FAQ
What is CSTL's average 12-month price target?+
The 6 active firms with a live target average $44.33 for Castle Biosciences Inc over the next 12 months, ranging from a $52.00 high to a $40.00 low, as of Nov 19, 2026.
Is CSTL stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 6 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CSTL?+
The Street-high target is $52.00 (Lake Street), and the Street-low is $40.00 (Roth Capital). The average of all 6 active-firm targets is $44.33.
How many active Wall Street firms cover CSTL?+
6 active firms have a recognized rating on Castle Biosciences Inc as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CSTL?+
Among analysts who currently cover CSTL, Puneet Souda of Leerink Partners has the strongest overall Quantellect track record (Rank #30). Their current call is Buy with a $35.00 target.
What is Castle Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $-0.30 per share (range $-0.46 – $-0.16) across 8 analysts. Full-year EPS is projected at $-0.82, rising to $-0.63 the following year.
How much revenue is Castle Biosciences Inc expected to report next quarter?+
Consensus revenue is $101.0M (range $92.2M – $107.2M). Full-year revenue is projected at $392.3M, growing to $434.0M next year.
Have analysts been upgrading or downgrading CSTL lately?+
As of Nov 19, 2026, 6 of 6 active firms rate CSTL a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CSTL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.